EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Using multiple biomarkers for patient enrichment in two-stage clinical designs

Fengqing Zhang, Jiangtao Gou

Contemporary Clinical Trials · 2025-09 · 156 · 108012

DOI: 10.1016/j.cct.2025.108012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Contemporary Clinical Trials, 2025-09. Verfasst von Fengqing Zhang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychological and Brain Sciences, Drexel University, Philadelphia, PA 19104, United States of America. Electronic address: fz53@drexel.…. Hauptthemen laut MEDLINE: Biomarkers, Research Design, Alzheimer Disease, Precision Medicine. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Villanova University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Enrichment strategies play a critical role in modern clinical trial design, especially as precision medicine advances the focus on patient-specific efficacy. By targeting biomarker-defined populations most likely to benefit, these strategies improve efficiency, reduce sample sizes and costs, accelerate timelines, and minimize unnecessary exposure to treatment-related risks and side effects. Recent developments in enrichment design have introduced biomarker randomness and accounted for the correlation structure between treatment effect and biomarker, resulting in a two-stage threshold enrichment design. However, existing methods are limited to a single continuous biomarker. While incorporating multiple biomarkers can improve the accuracy of target population identification, no study has examined how to incorporate multiple continuous biomarkers into enrichment designs due to the challenges in determining multiple thresholds. To fully utilize information from all relevant biomarkers, we propose novel two-stage enrichment designs capable of handling two or more continuous biomarkers. Our framework accommodates two popular treatment effect metrics including average treatment effect (ATE) and the standardized ATE. We illustrate our method using a hypothetical clinical trial involving early-stage Alzheimer's patients and assess the impact of stage one sample size on threshold estimation through a simulation study. Overall, our proposed two-stage enrichment designs offer researchers greater flexibility in integrating multiple continuous biomarkers. The findings from our study provide valuable insights for the advancement of enrichment trial methodology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BiomarkersResearch DesignAlzheimer DiseasePrecision MedicineClinical Trials as TopicHumansSample Size

Stichwörter der Autor:innen

Enrichment clinical trialsExperimental designMultiple biomarkersPrecision medicineThreshold estimation

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Department of Psychological and Brain Sciences, Drexel University, Philadelphia, PA 19104, United States of America. Electronic address: fz53@drexel.edu.
  • Department of Mathematics and Statistics, Villanova University, Villanova, PA 19085, United States of America.

Förderung

  • Villanova University

Zitieren

APA

Zhang, F., & Gou, J. (2025). Using multiple biomarkers for patient enrichment in two-stage clinical designs. Contemporary Clinical Trials, 156, 108012. https://doi.org/10.1016/j.cct.2025.108012

Vancouver

Zhang F, Gou J. Using multiple biomarkers for patient enrichment in two-stage clinical designs. Contemporary Clinical Trials. 2025;156:108012. doi:10.1016/j.cct.2025.108012

BibTeX
@article{Zhang2025,
  author = {Zhang, Fengqing and Gou, Jiangtao},
  title = {Using multiple biomarkers for patient enrichment in two-stage clinical designs},
  journal = {Contemporary Clinical Trials},
  year = {2025},
  volume = {156},
  pages = {108012},
  doi = {10.1016/j.cct.2025.108012}
}
Kostenlos starten →